With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
The Indiana University School of Medicine will help oversee a three-year, $30 million concussion study being funded by the Indianapolis-based NCAA and the U.S. Defense Department.
Health care professionals and advocates for the poor voiced praise and support Wednesday for a plan by Gov. Mike Pence to expand the state’s Healthy Indiana Plan to provide more insurance coverage to Hoosiers.
Indiana ranks 10th in the nation for the highest spending on health care and 10th in the nation for the number of adults missing six or more teeth. That’s not a coincidence. Hoosiers do a poor job of taking care of themselves, and we end up paying for it in higher taxes and health insurance premiums.
Getting everyone into the same room prior to surgeries is cutting costs and improving health.
The 5-year-old firm has pledged to invest $20 million to double the size of its corporate headquarters in Indianapolis and lease real estate for a series of 3,500-square-foot health clinics across the state.
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
Radiopharmaceuticals maker Zevacor Molecular plans to open a $40 million isotope-production facility in Noblesville, creating nearly 50 good-paying jobs within five years.
U.S. Sen. Joe Donnelly said administrators at Indiana's VA hospitals have told him they don't have the same kind of problems as the 26 veterans facilities across the country facing complaints about long waits and backlogs.
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
Two public hearings are scheduled this week on Gov. Mike Pence's plan to use Medicaid funds to expand the Healthy Indiana Plan to provide insurance under the federal health care overhaul.
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
RANAC Corp., a small firm in Indianapolis, cut its spending on health benefits 25 percent after dropping its group health plan. Could it be a sign of things to come?
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
The health insurance expansion Gov. Mike Pence is touting relies on federal Medicaid money and meets federal Medicaid requirements, but the Republican governor insists it's not Medicaid.
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
Initial 2015 premiums filed for the Obamacare exchanges in Indiana ranged from as high as a 46-percent hike to as low as a 9-percent cut. Anthem Blue Cross and Blue Shield wants an average increase of 9.7 percent.
Gov. Pence's HIP 2.0 plan is nothing less than an attempt to roll back liberal policy on low-income health benefits as far as currently possible–and to get other states to follow suit. It might even be an opening bid for president.
The $30 million project at Columbus Regional Hospital will expand its emergency department and cancer center.
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
